esophageal cancer foregut cancer
Conditions
Interventions
None listed
Sponsors
Universitair Medisch Centrum Groningen
Eligibility
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: -histological documented cancer of the esophagus or gastroesophageale junction (GEJ) - locally curable disease without distant metastases (M1b excluded) planned for high dose radiotherapy with or without chemotherapy - no previous or concurrent malignancy (except for basal cell ca. of the skin or in situ ca. of the cervix or superficial bladder ca. (pTa) in the past five years. - previously untreated patients (except induction chemotherapy) - no evidence of serious active infections - age >= 18 years - written informed consent to participate in the study - patients must have an WHO performance status 0-2 - all patients must be evaluated by a radiation oncologist prior to enrollment to ensure that the patient is an appropriate candidate for radiation therapy.
Exclusion criteria
Exclusion criteria: - known distant metastases - previous or concurrent malignancy (except for basal cell ca. of the skin or in situ ca. of the cervix or superficial bladder ca. (pTa) in the past five years - prior chest or upper abdominal radiotherapy, prior systemic chemotherapy, or prior esophageal or gastric surgery. - evidence of serious active infections - dementia or altered mental status that would prohibit the understanding and giving of informed consent -pregnant or lactating women. sexually active patients of childbearing potential must implement effective contraceptive practices during the study while in this study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| In what proportion of patients with a locoregional recurrence, observed at 6, 12 or 18 months after treatment, do recurrences occur outside the PET/CT-based CTV and can be considered as unpreventable? | — |
Countries
Netherlands
Outcome results
None listed